Polymyositis and dermatomyositis risk factors: Difference between revisions
Jump to navigation
Jump to search
m Bot: Removing from Primary care |
|||
| Line 41: | Line 41: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
Latest revision as of 23:47, 29 July 2020
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis risk factors On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis risk factors |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Common risk factors in the development of polymyositis and dermatomyositis include environmental factors such as infection, malignancy, and drug toxicities from statins or immune checkpoint inhibitors.
Risk Factors
- Common risk factors in the development of polymyositis and dermatomyositis include environmental factors such as infection, malignancy, and drug toxicities from statins or immune checkpoint inhibitors.[1][2][3][4][5]
Common Risk Factors
- Common risk factors in the development of polymyositis and dermatomyositis include:[1][2][3][4][5]
- Viral infections such as:
- Malignancy such as:
- Medications such as:
- Statins
- Immune checkpoint inhibitors such as:
- Ipilimumab
- Pembrolizumab
- Interferon-alpha
- IL-2 therapy
Less Common Risk Factors
- Less common risk factors in the development of polymyositis and dermatomyositis include:[6]
- Tobacco smoking (association with interstitial lung disease and rise in anti-Jo-1 antibody)
- Maternal smoking during pregnancy (risk factor for a juvenile dermatomyositis)
References
- ↑ 1.0 1.1 Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.
- ↑ 2.0 2.1 Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort". Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.
- ↑ 3.0 3.1 Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). "The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis". Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.
- ↑ 4.0 4.1 Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ 5.0 5.1 Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). "Polymyositis–Dermatomyositis-associated Interstitial Lung Disease". American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.
- ↑ Schiffenbauer, Adam; Faghihi-Kashani, Sara; O’Hanlon, Terrence P.; Flegel, Willy A.; Adams, Sharon D.; Targoff, Ira N.; Oddis, Chester V.; Ytterberg, Steven R.; Aggarwal, Rohit; Christopher-Stine, Lisa; Shamim, Ejaz A.; Dellaripa, Paul F.; Danoff, Sonye K.; Mammen, Andrew; Miller, Frederick W. (2018). "The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis". Seminars in Arthritis and Rheumatism. doi:10.1016/j.semarthrit.2018.02.003. ISSN 0049-0172.